IPM Product Pipeline

Since our inception in 2002, IPM’s pipeline has included products based on antiretrovirals (ARVs) — the same types of drugs that have proven successful in treating HIV/AIDS and preventing mother-to-child transmission in millions of people around the world.

The pipeline of ARV compounds at IPM is a result of our partnerships with pharmaceutical companies. Through royalty-free licensing agreements, we have access to eight drugs, or active pharmaceutical ingredients, with a variety of mechanisms of action against HIV infection.

The table below provides information on how IPM compounds work and their stage of development at IPM. Our clinical trials page lists IPM clinical trials that are currently under way.

 

IPM-licensed ARVs
Compound License Mechanism of action IPM development stage
Dapivirine Janssen R&D Ireland (previously Tibotec) NNRTI: Reverse transcription
  • Clinical: Phase III (dapivirine ring)
  • Phase I/II- completed    (dapivirine gel)
L167, L872, L882 Merck CCR5: Cell Attachment
  • Early preclinical
Tenofovir Gilead NRTI: Reverse transcription 
  • Preclinical*
BMS793 BMS gp120: Cell attachment
  • Preclinical
Maraviroc Viiv Healthcare CCR5: Cell Attachment
  • Clinical: Phase I- completed (maraviroc ring; dapivirine-maraviroc ring)
L-644 peptide Merck gp41: Cell fusion
  • Early preclinical

* Compound is in different stages of development by other organizations

 

IPM’s active compounds target different steps in viral replication

The candidate microbicides in IPM’s product pipeline target three different steps in the viral replication cycle: attachment, fusion, and reverse transcription.

  • Cell attachment: Preventing the virus from attaching to human cells
  • Cell fusion: Preventing the virus from entering human cells
  • Reverse transcription: Preventing the virus from reproducing inside human cells  

Learn more about how microbicides work.